NCT01960413View on ClinicalTrials.gov

Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions
DRUG

Montelukast added to Hydroxyurea

DRUG

Placebo added to Hydroxyurea

Trial Locations (2)

53226

Medical College of Wisconsin, Milwaukee

37232-9000

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

Medical College of Wisconsin

OTHER

collaborator

Versiti

OTHER

lead

Vanderbilt University Medical Center

OTHER

NCT01960413 - Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia | Biotech Hunter | Biotech Hunter